{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:33:51Z","timestamp":1772253231651,"version":"3.50.1"},"reference-count":12,"publisher":"Sociedade Brasileira de Cardiologia","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Bras. Cardiol."],"abstract":"<jats:p>Resumo  Fundamento: O fondaparinux \u00e9 um anticoagulante eficaz e seguro usado no tratamento de s\u00edndromes coronarianas agudas (SCAs). No entanto, devido \u00e0 baixa representatividade de indiv\u00edduos obesos em ensaios cl\u00ednicos, os efeitos de se aplicar os resultados desse medicamento nesta popula\u00e7\u00e3o continuam incertos.  Objetivos: Comparar o fondaparinux \u00e0 enoxaparina no tratamento de obesos com SCA.  M\u00e9todos: Este \u00e9 um estudo do tipo coorte retrospectivo, incluindo indiv\u00edduos obesos (IMC \u2265 30 Kg\/m2) internados com Infarto do Mioc\u00e1rdio sem Eleva\u00e7\u00e3o do Segmento ST (IAMSSST) ou Angina Inst\u00e1vel (AI) e tratados com fondaparinux ou enoxaparina entre 2010 e 2020. Os grupos que receberam fondaparinux e enoxaparina foram comparados quanto suas caracter\u00edsticas cl\u00ednicas e laboratoriais usando o teste do qui-quadrado e o teste de Mann-Whitney, conforme apropriado. A incid\u00eancia dos desfechos prim\u00e1rios (morte, reinfarto, acidente vascular cerebral, sangramento maior) foi comparada entre os grupos. Um p&lt;0,05 foi considerado estatisticamente significativo em todas as an\u00e1lises.  Resultados: Um total de 367 pacientes obesos com IAMSSST ou AI foi inclu\u00eddo, dos quais 258 usaram fondaparinux e 109 usaram enoxaparina. A idade m\u00e9dia foi 64 \u00b1 12 anos, 52,9% eram do sexo masculino. A preval\u00eancia e diabetes, hipertens\u00e3o, dislipidemia, doen\u00e7a arterial coronariana pr\u00e9via, acidente vascular cerebral pr\u00e9vio, e implementa\u00e7\u00e3o de estrat\u00e9gia invasiva foi similar entre os grupos. A incid\u00eancia do desfecho prim\u00e1rio foi 4,7% no grupo fondaparinux e 5,5% no grupo enoxaparina (p = 0,729). N\u00e3o houve diferen\u00e7a entre os grupos quando os componentes do desfecho prim\u00e1rio foram analisados separadamente.  Conclus\u00e3o: Em uma amostra de pacientes obesos com IAMSSST ou AI, n\u00e3o houve diferen\u00e7a na ocorr\u00eancia do desfecho composto (morte, acidente vascular cerebral, reinfarto, sangramento maior) entre os pacientes que utilizaram fondaparinux ou enoxaparina.<\/jats:p>","DOI":"10.36660\/abc.20230793","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:44:22Z","timestamp":1728481462000},"source":"Crossref","is-referenced-by-count":0,"title":["Fondaparinux versus Enoxaparina no Tratamento de Pacientes Obesos com S\u00edndrome Coronariana Aguda"],"prefix":"10.36660","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-3476","authenticated-orcid":false,"given":"Beatriz Rocha","family":"Darz\u00e9","sequence":"first","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Costa da Silva","family":"Souza","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Queila Borges de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Hospital C\u00e1rdio Pulmonar,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-7937","authenticated-orcid":false,"given":"Jo\u00e3o Victor Santos Pereira","family":"Ramos","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9021-7657","authenticated-orcid":false,"given":"Mateus S.","family":"Viana","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil; Hospital C\u00e1rdio Pulmonar,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Sahade","family":"Darz\u00e9","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil; Hospital C\u00e1rdio Pulmonar,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9320-7999","authenticated-orcid":false,"given":"Luiz Eduardo Fonteles","family":"Ritt","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil; Hospital C\u00e1rdio Pulmonar,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","published-online":{"date-parts":[[2024,8]]},"reference":[{"key":"ref1","series-title":"The Top 10 Causes of Death, 2000-2019 [Internet]","year":"2020"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0002-9343(00)00712-9","article-title":"Trends in Treatment and Outcomes for Acute Myocardial Infarction: 1975-1995","volume":"110","author":"Heidenreich PA","year":"2001","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijpvm.IJPVM_122_20","article-title":"The Reduction of Mortality in Acute Myocardial Infarction: From Bed Rest to Future Directions","volume":"13","author":"Laforgia PL","year":"2022","journal-title":"Int J Prev Med"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/hrt.2008.153387","article-title":"Predicting Freedom from Clinical Events in non-ST-elevation Acute Coronary Syndromes: The Global Registry of Acute Coronary Events","volume":"95","author":"Brieger D","year":"2009","journal-title":"Heart"},{"issue":"38","key":"ref5","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes","volume":"44","author":"Byrne RA","year":"2023","journal-title":"Eur Heart J"},{"issue":"14","key":"ref6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes","volume":"354","author":"Yusuf S","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"ref7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of Fondaparinux on Mortality and Reinfarction in Patients with Acute ST-segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial","volume":"295","author":"Yusuf S","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"ref8","first-page":"681","article-title":"Antithrombotic Therapy in Obesity","volume":"110","author":"Badimon L","year":"2013","journal-title":"Thromb Haemost"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth Universal Definition of Myocardial Infarction (2018)","volume":"40","author":"Thygesen K","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"ref10","first-page":"239","article-title":"Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data","volume":"107","author":"Soeiro AM","year":"2016","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and Efficacy of Unfractionated Heparin versus Enoxaparin in Patients who are Obese and Patients with Severe Renal Impairment: Analysis from the ESSENCE and TIMI 11B Studies","volume":"146","author":"Spinler SA","year":"2003","journal-title":"Am Heart J"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1538-7836.2007.02565.x","article-title":"Effect of Obesity on Outcomes after Fondaparinux, Enoxaparin, or Heparin Treatment for Acute Venous Thromboembolism in the Matisse trials","volume":"5","author":"Davidson BL","year":"2007","journal-title":"J Thromb Haemost"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":["Fondaparinux versus Enoxaparin in the Treatment of Obese Patients with Acute Coronary Syndrome"],"link":[{"URL":"https:\/\/abccardiol.org\/wp-content\/uploads\/articles_xml\/0066-782X-abc-121-08-e20230793\/0066-782X-abc-121-08-e20230793.x81990.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:44:26Z","timestamp":1728481466000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/fondaparinux-versus-enoxaparina-no-tratamento-de-pacientes-obesos-com-sindrome-coronariana-aguda\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["S0066-782X2024000800310"],"URL":"https:\/\/doi.org\/10.36660\/abc.20230793","relation":{"is-translation-of":[{"id-type":"doi","id":"10.36660\/abc.20230793i","asserted-by":"subject"},{"id-type":"doi","id":"10.36660\/abc.20230793i","asserted-by":"object"}]},"ISSN":["1678-4170","0066-782X"],"issn-type":[{"value":"1678-4170","type":"electronic"},{"value":"0066-782X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"article-number":"e20230793"}}